VMT-α-NET
Neuroendocrine Tumors, Other SSTR2 Expressing Tumors
Phase 1/2Cohort 2 completed recruitment; Cohort 3 DLT cohort recruited; Under evaluation
Key Facts
Indication
Neuroendocrine Tumors, Other SSTR2 Expressing Tumors
Phase
Phase 1/2
Status
Cohort 2 completed recruitment; Cohort 3 DLT cohort recruited; Under evaluation
Company
About Perspective Therapeutics
Perspective Therapeutics is on a mission to transform cancer treatment with its innovative, image-guided targeted alpha-particle therapy platform. Formed in February 2023 from the merger of Viewpoint Molecular Targeting and Isoray, the company leverages proprietary Pb-212-based radiotherapies and a matched imaging agent (Pb-203) for a precise theranostic approach. Its clinical pipeline includes programs for neuroendocrine tumors (VMT-α-NET), melanoma (VMT01/02), and fibroblast activation protein (PSV359) positive solid tumors, positioning it at the forefront of the next generation of radiopharmaceuticals.
View full company profile